Cassels retires as chief administrator at Winship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Diane Cassels will retire as chief administrator of Winship Cancer Institute of Emory University after 24 years of service, having served in a number roles including including chief department administrator for radiation oncology and administrator for the Emory Clinic’s Section of Radiation Oncology and chief operating officer at the Emory Children’s Center and Department of Pediatrics.

Cassels was named Winship’s executive administrator in 2010, transitioning to Winship’s chief administrative officer in January 2016.

During her tenure, Winship doubled its clinical footprint and clinical patient volume, expanded its membership from 268 to 434, and expanded the infrastructure for the conduct of clinical trials and laboratory research.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login